Deep Learning seems to be the magical word today in biology and medicine. This technology is used for DNA exploration, pictures interpretation or even to predict future diseases. Deep Genomics is going further and annonces to use of Deep Learning for early-stage development of drugs for Mendelian disorders. As the founder, Brendan Frey, says, it could be a new step in drugs developement, and maybe a “really massive shake-up of pharmaceuticals” !

Deep Genomics, a Canadian company that uses machine learning to trace potential genetic causes for disease, announced Tuesday that it’s getting into drug development. It joins a growing list of AI companies betting that their techniques can help produce powerful new drugs by finding subtle signals in huge quantities of genomic data.

Source: An AI-Driven Genomics Company Is Turning to Drugs – MIT Technology Review

Nathalie, our CEO, will be present in Pharmaceutical Flow Cytometry and Imaging 2016 meeting. This 5th biennial meeting is organised by ELRIG and will be held at GlaxoSmithKline, Stevenage, UK on the 22 and 23 November. 4 topics will be discussed :

• Translational Flow Cytometry and Imaging in Drug Discovery and Development
• Big Data and Analytics
• Novel and Emerging Technologies
• Next generation Cytomics in Pharmaceutical Research

She hopes to see you during this interesting meeting!

%d bloggers like this: